Table 3.
The systemic chemotherapy and response for metastasis patients in our center.
| First line | Response | PFS a (months) | Second line | Response | PFS b (months) | Third line | Response | PFS c (months) | PFS d (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| CAPOX | PR | 16 | – | – | – | – | – | – | – | 24 |
| GEMOX | PD | 2 | – | – | – | – | – | – | – | 57 |
| FOLFIRINOX | PD | 2 | GP/nimotuzumab | SD | 2 | – | – | – | – | 61 |
| S1 | PR | 23 | – | – | – | – | – | – | – | 66 |
| AG | PD | 3 | FOLFIRINOX | PR | 6 | S1/PD-1 inhibitor | PD | 2 | 2 | 16 |
| GP e | PD | 2 | FOLFIRINOX | PR | 9 | Lenvatinib/PD-1 inhibitor | SD | 4 | – | 17 |
| FOLFIRINOX | PR | 9 | – | – | – | – | – | – | – | 32 |
| FOLFIRINOX e | PR | 18 | GP | PD | 1.5 | Olaparib | PD | 2 | 1 | 39 |
Abbreviations: AG, albumin-bound paclitaxel + gemcitabine; CAPOX, oxaliplatin + capecitabine; FOLFIRINOX, 5-FU + oxaliplatin + leucovorin + irinotecan; GEMOX, gemcitabine + oxaliplatin; GP, gemcitabine + cisplatin; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; S1, tegafur/gimeracil/potassium.
a
PFS for first-line chemotherapy.
b
PFS for second-line chemotherapy.
c
PFS for the third-line chemotherapy.
d
PFS for the forth-line chemotherapy.
e
Patients were detected with BRCA2 mutation.